Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-03-14
Recursion Pharmaceuticals, Inc.
Clinical-stage TechBio company using Recursion OS, automated labs and pharma collaborations to discover and develop small-molecule medicines.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof Drives the Re-Rating
The upside case is that owned data, wet-lab throughput and better partner monetization turn a discounted AI-biotech into a credible multi-asset company. The near-term reality is simpler: a few human proof points still decide whether the platform is compounding engine or expensive optionality.

Analysis

Thesis
Recursion is a discounted AI-biotech factory, not a thin software wrapper: if it converts proprietary wet-lab data and compute into one registrationally credible asset, a second human-proof asset, and more embedded partner monetization by 2031, equity value can compound meaningfully from today's depressed base.
Last Economy Alignment
Cheaper cognition helps because Recursion owns the data-generating lab loop and collaboration rights, not seat-priced software, but value still must survive clinical and regulatory proof.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.8x (from 5 most recent analyses)
Reasoning
This is a multi-bagger setup if the company graduates from 'cash plus optionality' to 'repeatable human proof.' The upside does not require platform perfection; it requires one lead asset to earn a credible registration path, one more internal asset to show clean human validation, and partner monetization to become more recurring and more embedded in workflow and data rights. That supports a 2-5x equity outcome over five years, but not a clean hypergrowth call yet.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is not compute access or lab throughput; it is whether Recursion can turn platform productivity into repeatable human clinical and regulatory proof before the balance sheet again becomes the story. If REC-4881 and a second asset validate, the model looks underpriced. If not, the company remains a cash-burning option portfolio with dilution risk.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
They own the labs, data and workflow that can turn cheaper AI thinking into more drug shots on goal, so better models help them more than most biotechs. But if those shots do not keep working in human studies, the software stays interesting and the value stays fragile.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case